MCID: AVN001
MIFTS: 61

Avian Influenza

Categories: Infectious diseases, Muscle diseases, Oral diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Avian Influenza

MalaCards integrated aliases for Avian Influenza:

Name: Avian Influenza 12 58 3 15 17
Influenza in Birds 44 70
Bird Flu 12 42
Avian Flu 12

Characteristics:

Orphanet epidemiological data:

58
avian influenza
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare respiratory diseases
Rare infectious diseases


Summaries for Avian Influenza

MedlinePlus : 42 Birds, just like people, get the flu. Bird flu viruses infect birds, including chickens, other poultry, and wild birds such as ducks. Usually bird flu viruses only infect other birds. It is rare for people to get infected with bird flu viruses, but it can happen. Two types, H5N1 and H7N9, have infected some people during outbreaks in Asia, Africa, the Pacific, the Middle East, and parts of Europe. There have also been some rare cases of other types of bird flu affecting people in the United States. Most of the people who get bird flu have had close contact with infected birds or with surfaces that have been contaminated by the birds' saliva, mucous, or droppings. It is also possible to get it by breathing in droplets or dust that contain the virus. Rarely, the virus has spread from one person to another. It may also be possible to catch bird flu by eating poultry or eggs that are not well cooked. Bird flu illness in people can range from mild to severe. Often, the symptoms are similar to the seasonal flu, such as Fever Cough Sore throat Runny or stuffy nose Muscle or body aches Fatigue Headaches Eye redness (or conjunctivitis) Difficulty breathing In some cases, bird flu can cause serious complications and death. As with seasonal flu, some people are at higher risk for serious illness. They include pregnant women, people with weakened immune systems, and adults 65 and older. Treatment with antiviral medicines may make the illness less severe. They may also help prevent the flu in people who were exposed to it. There is currently no vaccine available to the public. The government does have a supply of a vaccine for one type of H5N1 bird flu virus and could distribute it if there was an outbreak that spread easily from person to person. Centers for Disease Control and Prevention

MalaCards based summary : Avian Influenza, also known as influenza in birds, is related to influenza and conjunctivitis, and has symptoms including vomiting, fever and cough. An important gene associated with Avian Influenza is FURIN (Furin, Paired Basic Amino Acid Cleaving Enzyme), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lactitol and Aluminum hydroxide have been mentioned in the context of this disorder. Affiliated tissues include eye, lung and t cells, and related phenotypes are fatigue and fever

Disease Ontology : 12 An influenza that results in infection located in respiratory tract of humans, domestic and wild birds, has material basis in Influenza A virus, which is transmitted by contact with infected poultry. Five strains of avian influenza A viruses (H5N1, H7N3, H7N2, H7N7 and H9N2) are known to cause human infections. The infection has symptom fever, has symptom cough, has symptom sore throat, has symptom muscle aches, has symptom nausea, has symptom diarrhea, has symptom vomiting, has symptom neurologic changes, has symptom pneumonia, and has symptom acute respiratory distress.

CDC : 3 Avian influenza refers to the disease caused by infection with avian (bird) influenza (flu) Type A viruses. These viruses occur naturally among wild aquatic birds worldwide and can infect domestic poultry and other bird and animal species. Avian flu viruses do not normally infect humans. However, sporadic human infections with avian flu viruses have occurred. The links below offer more information about avian influenza.

Wikipedia : 73 Avian influenza, known informally as avian flu or bird flu, is a variety of influenza caused by viruses... more...

Related Diseases for Avian Influenza

Diseases related to Avian Influenza via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 422)
# Related Disease Score Top Affiliating Genes
1 influenza 32.2 TNF NEU1 IVNS1ABP ISG15 IRF7 IL6
2 conjunctivitis 31.6 TNF IL6 CXCL8
3 newcastle disease 31.6 TNFSF10 TNF NEU1 IVNS1ABP IRF7 IFNA1
4 adult respiratory distress syndrome 31.5 TNF SFTPD IL6 CXCL8
5 swine influenza 31.5 TNF NEU1 IFNA1 DDX58
6 bronchitis 31.5 TNF IL6 CXCL8 CXCL10
7 disease by infectious agent 31.4 TNF SFTPD IL6 IFNA1 CCR5
8 plague 31.4 TNF IL6 DDX58 CCR5
9 meningoencephalitis 31.2 TNF IL6 CXCL10
10 encephalitis 31.0 TNF IL6 DDX58 CXCL10 CCR5
11 pneumonia 31.0 TNF SFTPD NEU1 IL6 CXCL8 CXCL10
12 severe acute respiratory syndrome 31.0 TNF IL6 IFNA1 FURIN DDX58 CXCL8
13 tracheitis 30.9 TNF IL6 FURIN CXCL8
14 viral pneumonia 30.9 TNF SFTPD IL6 DDX58 CXCL8 CXCL10
15 bacterial infectious disease 30.9 TNF ISG15 IL6 CXCL8
16 middle east respiratory syndrome 30.9 ISG15 FURIN CXCL10
17 respiratory failure 30.9 TNF SFTPD NEU1 JUN IL6 CXCL8
18 west nile virus 30.9 IFNA1 DDX58 CCR5
19 stomatitis 30.9 TNF IL6 IFNA1 DDX58 CXCL8
20 encephalomalacia 30.7 TNF IL6 CXCL8
21 vaccinia 30.7 TNF STAT2 ISG15 IRF7 IL6 IFNA1
22 bacterial pneumonia 30.6 TNF SFTPD NEU1 IL6 CXCL8
23 myositis 30.6 TNF IL6 IFNA1 CXCL8
24 diarrhea 30.6 TNF IL6 IFNA1 CXCL8
25 chlamydia 30.6 TNF IL6 CXCL8
26 gastroenteritis 30.6 TNF IL6 IFNA1 CXCL8
27 bronchopneumonia 30.6 TNF IL6 CXCL8
28 toxic shock syndrome 30.6 TNF IL6 CXCL8
29 dengue disease 30.6 TNF IVNS1ABP IFNA1
30 neutropenia 30.6 TNF IL6 IFNA1 CXCL8
31 parainfluenza virus type 3 30.5 NEU1 IFNA1 DDX58
32 rabies 30.5 STAT2 IRF7 IFNA1 DDX58 CXCL10
33 chikungunya 30.4 TNF IL6 FURIN DDX58
34 lung disease 30.4 TNF SFTPD IL6 CXCL8 CXCL10 CCR5
35 salmonellosis 30.4 TNF JUN IL6 CXCL8
36 streptococcal toxic-shock syndrome 30.4 TNF IL6 CXCL8
37 bronchiolitis 30.4 TNF SFTPD IL6 IFNA1 CXCL8 CXCL10
38 west nile fever 30.4 IFNA1 CXCL10 CCR5
39 leptospirosis 30.4 TNF IL6 CXCL8
40 ebola hemorrhagic fever 30.4 IFNA1 FURIN DDX58 CXCL10
41 cryptogenic organizing pneumonia 30.3 TNF SFTPD CXCL8
42 hepatitis e 30.3 TNF ISG15 DDX58
43 pericarditis 30.3 TNF IL6 CXCL8
44 exanthem 30.3 TNF IL6 IFNA1 CXCL8
45 lyme disease 30.3 TNF IRF7 IL6 IFNA1
46 thrombocytopenia 30.2 TNF STAT2 IRF7 IL6 IFNA1 CXCL8
47 coccidiosis 30.2 TNF IL6 CXCL8 CCR5
48 acquired immunodeficiency syndrome 30.2 TNF IL6 IFNA1 CCR5
49 bronchiolitis obliterans 30.2 TNF SFTPD IL6 CXCL8
50 measles 30.2 TNF STAT2 IRF7 IL6 IFNA1 DDX58

Graphical network of the top 20 diseases related to Avian Influenza:



Diseases related to Avian Influenza

Symptoms & Phenotypes for Avian Influenza

Human phenotypes related to Avian Influenza:

58 31 (show all 42)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 58 31 hallmark (90%) Very frequent (99-80%) HP:0012378
2 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
3 myalgia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003326
4 pharyngitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0025439
5 thrombocytopenia 58 31 frequent (33%) Frequent (79-30%) HP:0001873
6 lymphopenia 58 31 frequent (33%) Frequent (79-30%) HP:0001888
7 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
8 hypoxemia 58 31 frequent (33%) Frequent (79-30%) HP:0012418
9 elevated c-reactive protein level 58 31 frequent (33%) Frequent (79-30%) HP:0011227
10 pulmonary infiltrates 58 31 frequent (33%) Frequent (79-30%) HP:0002113
11 nonproductive cough 58 31 frequent (33%) Frequent (79-30%) HP:0031246
12 ground-glass opacification on pulmonary hrct 58 31 frequent (33%) Frequent (79-30%) HP:0025179
13 vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002013
14 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
15 chest pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0100749
16 conjunctivitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000509
17 respiratory failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0002878
18 pneumonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002090
19 pleural effusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0002202
20 diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002014
21 spontaneous abortion 58 31 occasional (7.5%) Occasional (29-5%) HP:0005268
22 productive cough 58 31 occasional (7.5%) Occasional (29-5%) HP:0031245
23 increased lactate dehydrogenase level 31 occasional (7.5%) HP:0025435
24 encephalitis 58 31 very rare (1%) Very rare (<4-1%) HP:0002383
25 congestive heart failure 58 31 very rare (1%) Very rare (<4-1%) HP:0001635
26 hepatitis 58 31 very rare (1%) Very rare (<4-1%) HP:0012115
27 elevated hepatic transaminase 58 31 very rare (1%) Very rare (<4-1%) HP:0002910
28 elevated serum creatine kinase 58 31 very rare (1%) Very rare (<4-1%) HP:0003236
29 meningitis 58 31 very rare (1%) Very rare (<4-1%) HP:0001287
30 sepsis 58 31 very rare (1%) Very rare (<4-1%) HP:0100806
31 hypoalbuminemia 58 31 very rare (1%) Very rare (<4-1%) HP:0003073
32 tachypnea 58 31 very rare (1%) Very rare (<4-1%) HP:0002789
33 respiratory distress 58 31 very rare (1%) Very rare (<4-1%) HP:0002098
34 pneumothorax 58 31 very rare (1%) Very rare (<4-1%) HP:0002107
35 acute kidney injury 58 31 very rare (1%) Very rare (<4-1%) HP:0001919
36 disseminated intravascular coagulation 58 31 very rare (1%) Very rare (<4-1%) HP:0005521
37 rhabdomyolysis 58 31 very rare (1%) Very rare (<4-1%) HP:0003201
38 myelitis 58 31 very rare (1%) Very rare (<4-1%) HP:0012486
39 dyspnea 58 Occasional (29-5%)
40 cough 58 Very frequent (99-80%)
41 leukopenia 58 Frequent (79-30%)
42 increased lactate dehydrogenase activity 58 Occasional (29-5%)

Symptoms:

12
  • vomiting
  • fever
  • cough
  • pneumonia
  • diarrhea
  • nausea
  • sore throat
  • muscle aches
  • neurologic changes
  • acute respiratory distress

UMLS symptoms related to Avian Influenza:


fever; pruritus; snoring; coughing

MGI Mouse Phenotypes related to Avian Influenza:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.21 CCR5 CRK CXCL10 FURIN IL6 IVNS1ABP
2 homeostasis/metabolism MP:0005376 10.2 CCR5 CRK CXCL10 DDX58 IL6 IRF7
3 hematopoietic system MP:0005397 10.18 CCR5 CXCL10 DDX58 FURIN IL6 IRF7
4 immune system MP:0005387 10.1 CCR5 CXCL10 DDX58 FURIN IL6 IRF7
5 digestive/alimentary MP:0005381 10.01 CCR5 CRK DDX58 FURIN IL6 PCSK5
6 mortality/aging MP:0010768 9.86 CCR5 CRK CXCL10 DDX58 FURIN IL6
7 liver/biliary system MP:0005370 9.76 CCR5 DDX58 FURIN IL6 JUN NEU1
8 respiratory system MP:0005388 9.32 CCR5 CRK IL6 IVNS1ABP JUN NEU1

Drugs & Therapeutics for Avian Influenza

Drugs for Avian Influenza (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lactitol Approved, Investigational Phase 3 585-86-4 157355
2
Aluminum hydroxide Approved, Investigational Phase 2, Phase 3 21645-51-2
3
Formaldehyde Approved, Vet_approved Phase 2, Phase 3 50-00-0 712
4 Hemagglutinins Phase 3
5 Vaccines Phase 3
6 Immunologic Factors Phase 3
7 MF59 oil emulsion Phase 3
8 Pharmaceutical Solutions Phase 3
9 Gastrointestinal Agents Phase 3
10 Immunosuppressive Agents Phase 3
11 Cathartics Phase 3
12 Laxatives Phase 3
13
Aluminum sulfate Approved Phase 2 10043-01-3
14
Tocopherol Approved, Investigational Phase 2 1406-66-2
15
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2 59-02-9 14985
16 Tocotrienol Investigational Phase 2 6829-55-6
17 Antacids Phase 1, Phase 2
18 Anti-Ulcer Agents Phase 1, Phase 2
19 Adjuvants, Immunologic Phase 2
20 Tocotrienols Phase 2
21 Tocopherols Phase 2
22 Immunoglobulins Phase 2
23 Antibodies Phase 2
24 Rho(D) Immune Globulin Phase 2
25 Immunoglobulins, Intravenous Phase 2
26 gamma-Globulins Phase 2
27
Probenecid Approved, Investigational Phase 1 57-66-9 4911
28
Imiquimod Approved, Investigational Phase 1 99011-02-6 57469
29 Antirheumatic Agents Phase 1
30 interferons Phase 1
31 Agglutinins Phase 1
32 N-(2-aminoethyl)-5-isoquinolinesulfonamide Phase 1

Interventional clinical trials:

(show top 50) (show all 124)
# Name Status NCT ID Phase Drugs
1 A Phase 2/3 Double Blinded, Randomized, Placebo-controlled Study in Healthy Adult Volunteers in Vietnam to Examine the Safety and Immunogenicity of an Inactivated A/H5N1 Influenza Vaccine (IVACFLU-A/H5N1) Produced by IVAC Completed NCT02612909 Phase 2, Phase 3
2 A Phase 3 Randomized, Observer-Blind, Multi-center, Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age Completed NCT02839330 Phase 3
3 A Blinded, Randomized Phase 2/3 Study to Assess Immunogenicity and Safety of Two Different Dose Levels of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Healthy Japanese Adult Population Aged 18 to 59 Years Completed NCT01382329 Phase 2, Phase 3
4 Safety and Immunogenicity of Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age Completed NCT01310413 Phase 3
5 A Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1when Administered to Adult and Elderly Subjects With and Without Immunosuppressive Conditions Completed NCT02107807 Phase 3
6 A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects Completed NCT00434733 Phase 3
7 Safety and Tolerability of GSK 1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure Completed NCT01788228 Phase 3
8 SEA022 Oseltamivir Treatment in Children Under One Year of Age With Moderate or Severe Influenza Lower Respiratory Tract Infection - a Clinical and Pharmacokinetic Study. Withdrawn NCT01546935 Phase 2, Phase 3 Oseltamivir
9 Immunogenicity and Safety of an Alum-adjuvanted Inactivated H7N9 Influenza Vaccine: a Randomized, Blind, Placebo-controlled, a Phase II Clinical Trial Unknown status NCT03755427 Phase 2
10 A Single Center, Open-label, Phase I/II Study of Two 90 Microgram Doses of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses Unknown status NCT00417560 Phase 1, Phase 2
11 Immunogenicity And Safety Of An Alum-Adjuvanted Inactivated H7N9 Influenza Vaccine Unknown status NCT03369808 Phase 1, Phase 2
12 A Phase II, Randomized, Placebo-controlled, Observer-blind, Multi Center Study on the Safety and Immunogenicity of Novartis Tetravalent Influenza Vaccine (Containing Both Interpandemic Strains and H5N1) in Adults Aged 18 Years and Above Completed NCT00620815 Phase 2
13 A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A/H7N9 Inactivated Influenza Vaccines Administered Intramuscularly With or Without AS03 Adjuvant in Healthy Adults 19-50 Years of Age Completed NCT03589807 Phase 2 AS03
14 A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects Completed NCT03738241 Phase 2 AS03
15 A Phase II, Open-label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Booster Dose of -H5N1 (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccine in Non-elderly Adult and Elderly Subjects Completed NCT00561184 Phase 2
16 A Phase II, Randomized, Controlled, Observer-blind, Single-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of an H5N1 Influenza Vaccine in Subjects Aged 6 Months to 17 Years Completed NCT00537524 Phase 2
17 A Phase II Study in Healthy Adults 18-64 Years Old to Assess the Safety, Reactogenicity and Immunogenicity of a Seqirus A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without MF59(R) Adjuvant Completed NCT03682120 Phase 2 MF59 adjuvant
18 Evaluation of Priming Effects by Pandemic Live Attenuated Influenza Vaccine (LAIV Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2)) on the Subsequent Response to Inactivated H5N1 Vaccine in Healthy Thai Volunteers: A Non-Randomized, Open Label Study Completed NCT02229357 Phase 2
19 A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without AS03 Adjuvant Completed NCT03312231 Phase 2 AS03
20 A Phase II Study in Healthy Adults (19-64 Years of Age) to Assess the Safety, Reactogenicity and Immunogenicity of Sequential or Simultaneous Intramuscular Administration of an AS03-adjuvanted A/H7N9 Inactivated Influenza Vaccine With Seasonal Influenza Vaccine Completed NCT03318315 Phase 2 AS03
21 A Phase II Randomized, Partially-Blinded, Controlled Trial in Healthy Adults Aged 65 Years and Older to Assess the Safety, Reactogenicity, and Immunogenicity of an MF59-Adjuvanted, Monovalent Inactivated Influenza A/H7N9 Virus Vaccine Administered Intramuscularly at Different Intervals and Dosages Completed NCT02213354 Phase 2 MF59
22 A Phase II, Single Center, Exploratory Study to Evaluate Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With MF59-adjuvanted or Non-adjuvanted H5N3 Influenza Vaccines Completed NCT00478816 Phase 2
23 A Phase II Study to Evaluate and Compare the Immunogenicity of Monovalent Inactivated Influenza A/H7N9 Virus Vaccine Administered With and Without AS03 Adjuvant and Monovalent Inactivated Influenza A/H3N2v Virus Vaccine Administered Without Adjuvant in Healthy Adults Through Standard and Systems Biology Analyses Completed NCT02921997 Phase 2 AS03
24 A Phase I/II Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Anhui/1/13 (H7N9) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Adults With and Without Matrix-M1™ Completed NCT02078674 Phase 1, Phase 2
25 High-Dose Versus Standard-Dose Oseltamivir for the Treatment of Severe Influenza and Avian Influenza: A Phase II Double-Blind, Randomized Clinical Trial Completed NCT00298233 Phase 2 Oseltamivir
26 Characterization of Innate Immune Responses to AS03 Adjuvanted H5N1 Vaccine Compared to Non-adjuvanted H5N1 Vaccine Completed NCT01578317 Phase 1, Phase 2
27 A Trial to Evaluate the Immunogenicity of Accelerated Primary Vaccination With Monovalent A/Indonesia/5/05 (H5N1) Vaccine Antigen in Association With AS03 Adjuvant in Adults Aged 18-64 Completed NCT00695669 Phase 2
28 A Phase II, Randomized, Controlled, Open Label, Single-Center Study to Evaluate the Immunogenicity, Safety and Tolerability of an H5N1-vaccine and a Seasonal Influenza Vaccine in Adult Subjects Completed NCT00481065 Phase 2
29 A Phase 1/2 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Infants, Children and Adolescents Aged 6 Months to 17 Years Completed NCT01052402 Phase 1, Phase 2
30 A Multicenter, Open-Label Study to Assess the Immunogenicity and Safety of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Healthy Young Adults Primed With a Two-Vaccination of a Recombinant H5N1 Influenza HA Vaccine Completed NCT01195038 Phase 2
31 A Phase II Randomized Study of the Safety and Immunogenicity of Vaccination Strategies Using One or Two Clades and Different Schedules of H5N1 Unadjuvanted, Inactivated Subvirion Influenza Vaccines in H5 Naïve Healthy Adults Completed NCT00703053 Phase 2
32 An Open-Label Phase 1/2 Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule With a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Volunteers Aged 18 to 59 Years Completed NCT00895544 Phase 1, Phase 2
33 Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in European Children Completed NCT00884182 Phase 2
34 Phase II, Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of a Single Intramuscular Dose of Inactivated Influenza A/H7N9 Vaccine After Priming With Inactivated Influenza A/H7N7 Vaccine Completed NCT02586792 Phase 2
35 Immunogenicity and Safety Study of GSK Biologicals' Monovalent Pandemic H5N1 Vaccine 1557484A in Adults Aged 18 - 64 Years Completed NCT01416571 Phase 2
36 A Randomized, Double-Blinded, Phase I/II Study of the Safety, Reactogenicity, and Immunogenicity of an Inactivated Influenza Vaccine Derived From A/H5N1/Indonesia/05/05 (Clade 2) in Healthy Adults and Elderly Who Participated in a Previous A/H5N1/Vietnam/1203/2004 (Clade 1) Vaccine Study Completed NCT00680069 Phase 1, Phase 2
37 A Phase II, Randomized, Controlled, Double-blind, Multi-center, Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines Containing 3.75 µg or 7.5 μg of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects Completed NCT00914771 Phase 2
38 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without AS03 Adjuvant (HIPC: VAX-010) Completed NCT01910519 Phase 2
39 A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects Completed NCT02436928 Phase 1, Phase 2
40 A Phase 1/2, Randomized, Open-Label, Study to Assess the Immunogenicity and Safety of a Vaccine Enhancement Patch (VEP) When Administered With Two Doses of Intramuscular Inactivated Influenza H5N1 Vaccine in Healthy Adults Completed NCT01353534 Phase 1, Phase 2 Vaccine Enhancement Patch
41 Randomized, Double-Blinded, Phase 2 Study to Assess Safety & Immunogenicity of Stored Inactivated Monovalent Influenza A/Vietnam/H5N1 Virus Vaccine Administered Intramuscularly at Different Dose Levels Given With & Without Stored MF59® Adjuvant Completed NCT02680002 Phase 2
42 A Multicenter, Non-Blinded, Dose Escalation Study to Evaluate the Immunogenicity, Safety and Optimal Dose of Three Doses Regimen of Recombinant Influenza H5N1 Vaccine, After Two Vaccinations Given 3 Weeks Apart, in Healthy Young Adults. Completed NCT00980447 Phase 2
43 A Randomized, Double-Blinded, Placebo-Controlled, Phase I/II, Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Healthy Children Aged 2 Years Through 9 Years Completed NCT00133536 Phase 1, Phase 2 Placebo
44 A Phase II, Randomized, Observer-Blind,Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects. Completed NCT01776541 Phase 2
45 A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects. Completed NCT01766921 Phase 2
46 A Phase II, Randomized, Controlled, Observer-blind, Single-Center Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, and a Six Month Booster Dose of Two Surface Antigen Adjuvanted With MF59C.1 Influenza Vaccines Containing 7.5 Micrograms or 15 Micrograms of A/H5N1 Influenza Antigen and of a Non-adjuvanted Influenza Vaccine Containing 15 Micrograms of A/H5N1 Influenza Antigen, in Adults Completed NCT00382187 Phase 2
47 Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities Completed NCT00311649 Phase 1, Phase 2
48 A Randomized, Double-Blinded, Placebo-Controlled Phase I/II, Dose-Ranging Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Healthy Elderly Adults Completed NCT00230750 Phase 1, Phase 2 Placebo
49 A Randomized, Double-Blinded, Placebo-Controlled, Phase I/II, Dose-Ranging Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Healthy Adults Completed NCT00115986 Phase 1, Phase 2
50 A Phase II Randomized, Double-Blinded, Controlled Study in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of a Monovalent Influenza A/H7N9 Virus Vaccine Administered at Different Dosages Given With and Without AS03 and MF59 Adjuvants Completed NCT01942265 Phase 2 AS03;MF59

Search NIH Clinical Center for Avian Influenza

Cochrane evidence based reviews: influenza in birds

Genetic Tests for Avian Influenza

Anatomical Context for Avian Influenza

MalaCards organs/tissues related to Avian Influenza:

40
Eye, Lung, T Cells, Kidney, Endothelial, Heart, Skin

Publications for Avian Influenza

Articles related to Avian Influenza:

(show top 50) (show all 10911)
# Title Authors PMID Year
1
N-linked glycosylation at site 158 of the HA protein of H5N6 highly pathogenic avian influenza virus is important for viral biological properties and host immune responses. 61 42
33436086 2021
2
Glycosylation generates an efficacious and immunogenic vaccine against H7N9 influenza virus. 42 61
33362243 2020
3
Experiences and management of physician psychological symptoms during infectious disease outbreaks: a rapid review. 42
33568141 2021
4
The role of glycosylation in the N-terminus of the hemagglutinin of a unique H4N2 with a natural polybasic cleavage site in virus fitness in vitro and in vivo. 61
33538209 2021
5
Comparative pathogenicity and environmental transmission of recent highly pathogenic avian influenza H5 viruses. 61
33350337 2021
6
Emergence and spread of novel H5N8, H5N5 and H5N1 clade 2.3.4.4 highly pathogenic avian influenza in 2020. 61
33400615 2021
7
Mink is a highly susceptible host species to circulating human and avian influenza viruses. 61
33657971 2021
8
Pathogenic assessment of avian influenza viruses in migratory birds. 61
33666526 2021
9
A THz graphene metasurface for polarization selective virus sensing. 61
33612849 2021
10
Development of lateral flow assay based on anti-IBDV IgY for the rapid detection of Gumboro disease in poultry. 61
33577956 2021
11
Exploring the potential of foodborne transmission of respiratory viruses. 61
33397626 2021
12
Data on swan arrival, departure, and population size on the Asadokoro tidal flat, Aomori Prefecture, Japan, from 1956 to 2010. 61
33659589 2021
13
Establishment of a safe and convenient assay for detection of HA subtype-specific antibodies with PB2 gene-knockout influenza viruses. 61
33539845 2021
14
H7N9 influenza virus surveillance in Gansu, China in 2017. 61
33577861 2021
15
Development and application of a novel triplex protein microarray method for rapid detection of antibodies against avian influenza virus, Newcastle disease virus, and avian infectious bronchitis virus. 61
33576898 2021
16
Progress of public health policy regarding global infectious diseases over the past decade in Japan. 61
33472748 2021
17
Prioritizing smallholder animal health needs in East Africa, West Africa, and South Asia using three approaches: Literature review, expert workshops, and practitioner surveys. 61
33581421 2021
18
Efficacy of recombinant Marek's disease virus vectored vaccines with computationally optimized broadly reactive antigen (COBRA) hemagglutinin insert against genetically diverse H5 high pathogenicity avian influenza viruses. 61
33715903 2021
19
Isolation and characterization of two novel reassortant H5N6 avian influenza viruses from waterfowl in eastern China. 61
33598814 2021
20
Quantitative risk assessment of the introduction of low pathogenic avian influenza H5 and H7 strains into Poland via legal import of live poultry. 61
33588326 2021
21
Highly Pathogenic Avian Influenza Clade 2.3.4.4 Subtype H5N6 Viruses Isolated from Wild Whooper Swans, Mongolia, 2020. 61
33754986 2021
22
The effect of single amino acid substitution at position 220 in the hemagglutinin glycoprotein on avian influenza H7N9 candidate vaccine virus. 61
33606171 2021
23
The virulence modulator PA-X protein has minor effect on the pathogenicity of the highly pathogenic H7N9 avian influenza virus in mice. 61
33676094 2021
24
The Epidemiology, Virology, and Pathogenicity of Human Infections with Avian Influenza Viruses. 61
31964651 2021
25
Co-expression network analysis identifies innate immune signatures for Albizia julibrissin saponin active fraction-adjuvanted avian influenza vaccine. 61
33550033 2021
26
Probiotic Lactobacilli Enhance Immunogenicity of an Inactivated H9N2 Influenza Virus Vaccine in Chickens. 61
33236974 2021
27
Label-Free, Multiplex Glycan Microarray Biosensor for Influenza Virus Detection. 61
33559468 2021
28
Application of frozen and stored glutaraldehyde-fixed turkey red blood cells for hemagglutination and hemagglutination inhibition assays for the detection and identification of influenza viruses. 61
33333106 2021
29
Mammalian and Avian Host Cell Influenza A Restriction Factors. 61
33810083 2021
30
A proposal to leverage high-quality veterinary diagnostic laboratory large data streams for animal health, public health, and One Health. 61
33769139 2021
31
Design and Structure-Activity Relationship of a Potent Furin Inhibitor Derived from Influenza Hemagglutinin. 61
33738063 2021
32
An evaluation of the InDevR FluChip-8G insight microarray assay in characterizing influenza a viruses. 61
33731192 2021
33
Impact of Individual Viral Gene Segments from Influenza A/H5N8 Virus on the Protective Efficacy of Inactivated Subtype-Specific Influenza Vaccine. 61
33808583 2021
34
Reassortment with dominant chicken H9N2 influenza virus contributed to the fifth H7N9 virus human epidemic. 61
33731452 2021
35
Effect of fennel essential oil on performance, serum biochemistry, immunity, ileum morphology and microbial population, and meat quality of broiler chickens fed corn or wheat-based diet. 61
33530744 2021
36
Live and Wet Markets: Food Access versus the Risk of Disease Emergence. 61
33712334 2021
37
Virucidal activity of slightly acidic hypochlorous acid water toward influenza virus and coronavirus with tests simulating practical usage. 61
33705798 2021
38
Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adults. 61
33741987 2021
39
Genetic characteristics and pathogenicity of novel reassortant H6 viruses isolated from wild birds in China. 61
33454600 2021
40
H7N9 pandemic preparedness: A large-scale production of a split inactivated vaccine. 61
33550095 2021
41
Mutations during the adaptation of H7N9 avian influenza virus to mice lungs enhance human-like sialic acid binding activity and virulence in mice. 61
33515926 2021
42
Synergistic effect of Spirulina platensis and selenium nanoparticles on growth performance, serum metabolites, immune responses, and antioxidant capacity of heat-stressed broiler chickens. 61
33674946 2021
43
Synergistic use of florfenicol and Salvia miltiorrhiza polysaccharide can enhance immune responses in broilers. 61
33412284 2021
44
Immunosecurity: immunomodulants enhance immune responses in chickens. 61
33705619 2021
45
Economic evaluation of whole genome sequencing for pathogen identification and surveillance - results of case studies in Europe and the Americas 2016 to 2019. 61
33663647 2021
46
A Call for One Health in Medical Education: How the COVID-19 Pandemic Underscores the Need to Integrate Human, Animal, and Environmental Health. 61
33769340 2021
47
Major zoonotic diseases of public health importance in Bangladesh. 61
33650812 2021
48
Infection and risk factors of human and avian influenza in pigs in south China. 61
33744674 2021
49
Pathogen Presence in Wild Birds Inhabiting Landfills in Central Iran. 61
33783651 2021
50
Antibodies to Highly Pathogenic A/H5Nx (Clade 2.3.4.4) Influenza Viruses in the Sera of Vietnamese Residents. 61
33806156 2021

Variations for Avian Influenza

Expression for Avian Influenza

Search GEO for disease gene expression data for Avian Influenza.

Pathways for Avian Influenza

Pathways related to Avian Influenza according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 TNF STAT2 NEU1 JUN ISG15 IRF7
2
Show member pathways
13.84 TNFSF10 TNF STAT2 JUN IL6 CXCL8
3
Show member pathways
13.56 TNFSF10 TNF STAT2 JUN IL6 IFNA1
4
Show member pathways
13.3 TNFSF10 TNF JUN IL6 CXCL8 CXCL10
5
Show member pathways
13.22 TNF STAT2 ISG15 IRF7 IL6 IFNA1
6
Show member pathways
12.91 STAT2 JUN CXCL8 CXCL10 CRK CCR5
7 12.86 STAT2 JUN IL6 IFNA1 CXCL8 CRK
8 12.82 TNF STAT2 IRF7 IL6 IFNA1 DDX58
9
Show member pathways
12.76 TNFSF10 TNF JUN IL6 CXCL8
10
Show member pathways
12.71 TNF STAT2 JUN IRF7 IL6 IFNA1
11
Show member pathways
12.69 TNFSF10 TNF STAT2 SFTPD JUN IRF7
12
Show member pathways
12.62 TNF JUN IL6 CRK CCR5
13
Show member pathways
12.58 IRF7 IL6 IFNA1 DDX58 CXCL10
14
Show member pathways
12.56 STAT2 ISG15 IRF7 IFNA1 DDX58
15 12.54 TNF STAT2 IRF7 IFNA1 DDX58 CXCL10
16
Show member pathways
12.48 TNF ISG15 IRF7 IFNA1 DDX58 CXCL8
17 12.41 TNF JUN CXCL8 CRK
18
Show member pathways
12.39 TNF JUN IRF7 IL6 IFNA1 CXCL8
19
Show member pathways
12.34 TNF JUN IL6 CXCL8 CRK
20
Show member pathways
12.34 TNF JUN IL6 CXCL8 CXCL10
21
Show member pathways
12.31 TNFSF10 TNF IL6 CXCL8 CXCL10 CCR5
22
Show member pathways
12.25 TNF JUN IL6 CXCL8
23
Show member pathways
12.25 TNF JUN IRF7 IL6 CXCL8
24
Show member pathways
12.24 TNF STAT2 JUN IL6
25
Show member pathways
12.23 TNFSF10 TNF STAT2 IFNA1
26
Show member pathways
12.21 TNF STAT2 ISG15 IRF7 IL6 IFNA1
27 12.2 TNF JUN IL6 CXCL8
28
Show member pathways
12.1 TNF SFTPD JUN IL6 CXCL8 CXCL10
29
Show member pathways
12.07 TNFSF10 TNF STAT2 JUN ISG15 IRF7
30 12.06 TNF JUN IL6 CXCL8 CRK
31 12.03 TNF IL6 CXCL8 CXCL10
32 12 TNF JUN IL6 CXCL10
33 11.96 JUN IRF7 IL6 CXCL8
34 11.96 TNF STAT2 JUN IRF7 IL6 IFNA1
35 11.93 TNF JUN IL6 CXCL8
36 11.89 TNF JUN IL6 CXCL8
37 11.81 JUN IL6 CXCL8
38
Show member pathways
11.77 TNF JUN CXCL8
39
Show member pathways
11.77 TNF STAT2 JUN IL6
40 11.77 TNF JUN IL6 CXCL8
41 11.69 TNF IL6 CXCL8
42 11.68 JUN IL6 CXCL8 CRK
43
Show member pathways
11.66 TNF JUN IL6 CXCL8
44 11.64 TNF IL6 CXCL8
45 11.62 JUN IL6 CXCL8
46 11.58 JUN IL6 CXCL8
47 11.57 TNF IL6 CXCL8
48 11.54 TNFSF10 IL6 IFNA1
49 11.54 TNFSF10 TNF JUN IL6
50 11.52 TNF JUN IL6

GO Terms for Avian Influenza

Cellular components related to Avian Influenza according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 TNFSF10 TNF SFTPD PCSK6 PCSK5 IL6
2 extracellular region GO:0005576 9.4 TNFSF10 TNF SFTPD PCSK6 PCSK5 NEU1

Biological processes related to Avian Influenza according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 10 TNFSF10 TNF IL6 CXCL8 CXCL10 CCR5
2 viral process GO:0016032 9.98 STAT2 IVNS1ABP ISG15 IRF7 FURIN DDX58
3 inflammatory response GO:0006954 9.95 TNF IL6 CXCL8 CXCL10 CCR5
4 cell-cell signaling GO:0007267 9.92 TNFSF10 PCSK5 CXCL10 CCR5
5 regulation of cell proliferation GO:0042127 9.89 TNF STAT2 JUN CXCL10
6 cellular response to lipopolysaccharide GO:0071222 9.8 TNF IL6 CXCL8 CXCL10 CCR5
7 protein processing GO:0016485 9.79 PCSK6 PCSK5 FURIN
8 chemokine-mediated signaling pathway GO:0070098 9.78 CXCL8 CXCL10 CCR5
9 defense response GO:0006952 9.77 TNF STAT2 IFNA1 CXCL8 CXCL10
10 positive regulation of smooth muscle cell proliferation GO:0048661 9.76 TNF JUN IL6
11 type I interferon signaling pathway GO:0060337 9.76 STAT2 ISG15 IRF7 IFNA1
12 positive regulation of interleukin-8 production GO:0032757 9.74 TNF IL6 DDX58
13 humoral immune response GO:0006959 9.73 TNF IL6 IFNA1
14 peptide hormone processing GO:0016486 9.67 PCSK6 PCSK5 FURIN
15 embryonic digestive tract development GO:0048566 9.65 TNF PCSK5 CXCL8
16 response to virus GO:0009615 9.65 TNF IVNS1ABP IRF7 DDX58 CXCL10
17 positive regulation of neuroinflammatory response GO:0150078 9.63 TNF IL6
18 signal peptide processing GO:0006465 9.63 PCSK5 FURIN
19 secretion by cell GO:0032940 9.62 PCSK6 FURIN
20 negative regulation of lipid storage GO:0010888 9.6 TNF IL6
21 vascular endothelial growth factor production GO:0010573 9.58 TNF IL6
22 peptide biosynthetic process GO:0043043 9.54 PCSK5 FURIN
23 nerve growth factor production GO:0032902 9.51 PCSK6 FURIN
24 regulation of lipoprotein lipase activity GO:0051004 9.5 PCSK6 PCSK5 FURIN
25 defense response to virus GO:0051607 9.5 STAT2 ISG15 IRF7 IL6 IFNA1 DDX58
26 nerve growth factor processing GO:0032455 9.33 PCSK6 PCSK5 FURIN
27 cytokine-mediated signaling pathway GO:0019221 9.23 TNF STAT2 IL6 IFNA1 CXCL8 CXCL10

Molecular functions related to Avian Influenza according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.96 TNFSF10 TNF TMPRSS13 STAT2 SFTPD PCSK6
2 serine-type endopeptidase activity GO:0004252 9.62 TMPRSS13 PCSK6 PCSK5 FURIN
3 serine-type peptidase activity GO:0008236 9.46 TMPRSS13 PCSK6 PCSK5 FURIN
4 nerve growth factor binding GO:0048406 9.26 PCSK6 FURIN
5 cytokine activity GO:0005125 9.1 TNFSF10 TNF IL6 IFNA1 CXCL8 CXCL10

Sources for Avian Influenza

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....